Janssen Receives EC’s Approval for the Expanded Use of Stelara (Ustekinumab) to Treat Pediatric Patients with Moderate to Severe Plaque Psoriasis

 Janssen Receives EC’s Approval for the Expanded Use of Stelara (Ustekinumab) to Treat Pediatric Patients with Moderate to Severe Plaque Psoriasis

Janssen Receives EC’s Approval for the Expanded Use of Stelara (Ustekinumab) to Treat Pediatric Patients with Moderate to Severe Plaque Psoriasis

Shots:

  • The EC’s approval is based on P-III CADMUS Jr study assessing Stelara (SC) in 44 pediatric patients with mod. to sev. PsO aged 6–11 yrs. from 9 countries. The study follows its prior P-III CADMUS study
  • The P-III CADMUS Jr study results: @12wks. improvement in psoriasis and HrQOL; patients achieved PGA 0/1 (77.3%); PASI 75 (84.1%); PASI 90 (63.6%); change in CDLQI (-6.3). Following first administration of Stelara, patients were followed up to 52wks., improvement in PGA 0/1 (75.6%); PASI 75 (87.7%); PASI 90 (70.7%); CDLQI (58.3%) maintained @52wks.
  • Stelara is the first biologic targeting IL-12 and IL-23 cytokines and has received CHMP’s positive opinion on Dec 12, 2019. The approval for expanded use of Stelara addresses the unmet medical need of pediatric patients  

Click here ­to­ read full press release/ article | Ref: JNJ | Image: Business wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post